Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population by Wassilak, Steven et al.
MAJOR ARTICLE
Outbreak of Type 2 Vaccine-Derived Poliovirus
in Nigeria: Emergence and Widespread
Circulation in an Underimmunized Population
Steven Wassilak,1 Muhammad Ali Pate,2 Kathleen Wannemuehler,1 Julie Jenks,1 Cara Burns,1 Paul Chenoweth,1
Emmanuel Ade Abanida,2 Festus Adu,4 Marycelin Baba,5 Alex Gasasira,3 Jane Iber,1 Pascal Mkanda,3 A. J. Williams,1
Jing Shaw,1 Mark Pallansch,1 and Olen Kew1
1Centers for Disease Control and Prevention, Atlanta, Georgia; 2National Primary Health Care Development Agency and
3World Health Organization, Nigeria, Abuja; 4Department of Virology, College of Medicine, University of Ibadan, and 5University of
Maiduguri Teaching Hospital, Maiduguri, Nigeria
(See the article by Neal et al., on pages 889–90.)
Wild poliovirus has remained endemic in northern Nigeria because of low coverage achieved in the routine
immunization program and in supplementary immunization activities (SIAs). An outbreak of infection
involving 315 cases of type 2 circulating vaccine-derived poliovirus (cVDPV2; .1% divergent from Sabin 2)
occurred during July 2005–June 2010, a period when 23 of 34 SIAs used monovalent or bivalent oral poliovirus
vaccine (OPV) lacking Sabin 2. In addition, 21 ‘‘pre-VDPV2’’ (0.5%–1.0% divergent) cases occurred during this
period. Both cVDPV and pre-VDPV cases were clinically indistinguishable from cases due to wild poliovirus.
The monthly incidence of cases increased sharply in early 2009, as more children aged without trivalent OPV
SIAs. Cumulative state incidence of pre-VDPV2/cVDPV2 was correlated with low childhood immunization
against poliovirus type 2 assessed by various means. Strengthened routine immunization programs in countries
with suboptimal coverage and balanced use of OPV formulations in SIAs are necessary to minimize risks of
VDPV emergence and circulation.
The cornerstone of the Global Polio Eradication Initia-
tive is immunization of children with multiple doses of
oral poliovirus vaccine (OPV), via both routine immu-
nization (RI) and supplementary immunization activi-
ties (SIAs) [1]. The key advantages of OPV are ease of
administration and efﬁcient induction of mucosal im-
munity, thereby limiting poliovirus shedding and per-
son-to-person transmission [2]. Through widespread
implementation of this approach and with standardized
virologic surveillance, indigenous wild poliovirus
(WPV) transmission has stopped in all but 4 countries
(Nigeria, Pakistan, Afghanistan, and India) [1]. WPV
type 2 (WPV2) circulation apparently stopped in Africa
in the mid-1990s (F. Adu and C. Kofﬁ; unpublished
data),andWPV2waslastdetected(inIndia)in1999[3].
Despiteits advantages, OPV use carries the infrequent
risks of vaccine-associated paralytic poliomyelitis
among OPV recipients and their direct contacts [2] and
the emergence of genetically divergent vaccine-derived
polioviruses (VDPVs) [4, 5], both a consequence of
selection against the attenuated phenotype during in-
testinalreplication [6]. VDPVs areoperationally deﬁned
as OPV-related isolates having .1% nucleotide (nt)
sequencedivergence fromthe parentalOPVstraininthe
900-nt region encoding the major capsid surface
protein, VP1 [4, 5]. This arbitrary demarcation repre-
sents 1y e a ro fp o l i o v i r u s( P V )r e p l i c a t i o na f t e ra d -
ministrationoftheinitiatingOPVdose[7],substantially
longer than the normal postvaccination excretion
period of 4–6 weeks [2, 8]. VDPVs are further
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of transmission beyond close contacts [4, 5]. cVDPV outbreaks
have occurred in settings of widening susceptibility to >1p o -
liovirus serotype in association with weak RI programs and in
locations where the corresponding WPVs of the same serotype
have been eliminated [4, 5,9, 10]. The risk of cVDPVemergence
appears to be highest for the Sabin type 2 (Sabin 2) OPV strain
[4, 5, 10], particularly in areas with high densities of non-
immune persons, poor sanitation, and tropical or subtropical
climates [11].
Northern Nigeria had remained a major reservoir for WPV1
and WPV3 [12, 13], leading to extensive international spread of
WPV1 in 2003–2006 [14] and 2008–2009 [13, 15] and limited
WPV3 international spread in 2008–2009 [13, 15]. Low trivalent
OPV (tOPV) coverage in the RI program, suspension of SIAs in
some states in 2003–2004, and low coverage in SIAs have con-
tributed to ongoing WPV transmission [14]. To more efﬁciently
stop WPV1 and WPV3 transmission, monovalent OPV type 1
(mOPV1) was regularly used in SIAs starting in March 2006,
and mOPV3 was intermittently used starting in July 2007 [12,
13].DuringtheperiodJuly2005–June2010,11of34SIArounds
in northern Nigeria used tOPV, including only 4 rounds during
the period March 2006–April 2009.
In 2002, a case involving VDPV type 2 (VDPV2) was detected
in Plateau state, but no related cases involving VDPV2 or any
other VDPVs were detected over the next 4 years[16]. In August
2006, virologic investigations detected a cluster of acute ﬂaccid
paralysis (AFP) cases associated with Sabin 2-related isolates in
northern Nigeria; sequence analysis revealed that the isolates
were VDPVs [17]. Retrospective analyses found an early out-
break isolate in 2005, and continued screening through mid-
2010 detected a total of 315 VDPV2 case isolates. We found an
additional 21 cases with ‘‘pre-VDPV2’’ isolates (0.5%–1% VP1
divergent from Sabin 2), sporadically found in settings of high
OPV coverage.
Here, we describe epidemiologic characteristics of the out-
break of cVDPV2 infection in Nigeria during the period from
July 2005 through 30 June 2010, constituting the largest and
second-longest known cVDPV-associated outbreak [5, 17-21].
Furthermore,inaccordwiththeﬁndingsofJenkinsetal[21],we
compare clinical features of both VDPV2- and pre-VDPV2–
associated cases with WPV and non-polio AFP (NP-AFP) cases.
We then assess risks of the emergence and spread of cVDPV2 in
northern Nigeria and discuss measures needed to prevent fur-
ther cVDPV outbreaks.
METHODS
Background
Nigeria,the mostpopulouscountryin Africa(population, 140
million) [22], has a population growth rate of 2.4% [23]. Pop-
ulation densities (national mean, 152 persons/km
2)v a r yw i d e l y
by state and are highest in the states of the tropical south
(median, 390 persons/km
2; highest, 2162 persons/km
2 [in Lagos
Figure 1. Map of Nigeria showing state geopolitical zones and population density by LandScan [36].
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km
2; highest, 449 persons/km
2 [in Kano state]) [22-24]. The 36
states (plus the Federal Capital Territory) grouped into 6 zones
(Figure 1) are responsible for health policy implementation and
secondary health care, and the 774 local government areas
(LGAs) are responsible for primary health care. Government
health expenditures account for 1.7% of gross domestic product
(US$1089 per capita in 2009) [25, 26].
The RI program, begun in 1979, includes 4 doses of tOPV
given at birth and at 6, 10, and 14 weeks of age. National average
coverage for >3 OPV doses (OPV3) rose above 20% in 1986,
increased to 55% in 1990, then decreased to 20% in 1999 [27].
SIAs with OPV began in 1997 [28]; since then, coverage with
three doses of diphtheria-tetanus-pertussis vaccine (DTP3)
provides a more accurate determination of OPV3 delivery in the
RI program. Nationally, estimated DTP3 coverage gradually
increased from 20% in 1997 to 40% in 2006, remaining
at 42% in 2009 [29]. Survey results have been variable.
Demographic and Health Surveys in both 2003 and 2008 and
a UNICEF survey in 2007 reported <35% national DTP3 cov-
erage in children aged 12–23 months, whereas large national
immunization coverage surveys (NICS) in 2003 and 2006 re-
ported DTP3 coverage in children aged 12–23 months of 40%
and 54%, respectively [29-33]. Increases in the estimated na-
tional average coverage were observed in serial NICSs and De-
mographic and Health Surveys since 2003, with wide variation
in coverage by state, and increasing coverage along a north-
south gradient [30-32]. NICS reported average DTP3 coverage
for northern states at 24.4% (range, 4.3%–58.9%) in 2003, and
38.3% (range, 9.2%–83.5%) in 2006; coverage in southern states
was 62.1% (range, 33.6%–87.5%) in 2003, and 71.5% (range,
50.6%–93.1%) in 2006 [31, 32].
Case Ascertainment and Classification
During 1996–1998, the Nigerian Ministry of Health and the
World Health Organization (WHO) instituted an AFP surveil-
lance system to detect paralytic poliomyelitis. Local government
area surveillance ofﬁcers perform investigations of reported AFP
cases,whichincludealimitedclinicalhistory,clinicalevaluation,
and collection of stool specimens for virologic testing; caretakers
of case patients with AFP provide a recall history of the total
number of OPV doses received prior to paralysis. Clinical
reevaluation for residual paralysis at least 60 days after onset is
generally performed when stool specimens are inadequate (ie,
because of late collection, insufﬁcient material, or improper
transport) [34] and is otherwise performed inconsistently. AFP
surveillance quality is monitored by WHO performance stand-
ards [35].
In this report, AFP cases are classiﬁed as follows: WPV
cases, WPV1 or WPV3 isolated from >1 stool specimen (in-
cludes VDPV2 and pre-VDPV2 coinfections) [13]; VDPV2
cases, Sabin 2-related PV with >10 nt VP1 substitutions
(.1% divergent) [4, 5] isolated from >1 stool specimen and
no WPV isolated; ‘‘pre-VDPV2’’ cases, Sabin 2-related PV
with 5–9 nt VP1 substitutions (0.5%–1% divergent) isolated
from >1 stool specimen and no WPV isolated; and NP-AFP
cases, no WPV, VDPV, or pre-VDPV isolated. If stool speci-
mens were inadequate and if the case patient had residual
paralysis after 60-days, died, or was lost to follow-up, cases
were referred to an expert panel for classiﬁcation as either
polio compatible (excluded from our analyses) or NP-AFP
cases. All VDPV2swere vaccine/nonvaccine recombinantsand
were counted as outbreak cVDPV2s. Among 27 pre-VDPV2s,
21 were vaccine/nonvaccine recombinants typical of cVDPVs
[2, 4] whose cases clustered temporally and geographically
with the cVDPV2s and were included in our analyses. Six pre-
VDPV2 isolates (including 2 from the southern states of Lagos
and Anambra) that were nonrecombinant or vaccine/vaccine
recombinants were excluded from our analyses. Detailed vi-
rologic characterization of all cVDPV2/pre-VDPV2 isolates
will be described elsewhere (Burns et al; unpublished data).
All AFP cases for which vaccine/nonvaccine recombinant
cVDPV2/pre-VDPV2 and WPV were isolated were included
in the description of the outbreak time course and geographic
distribution but were classiﬁed as WPV cases. Because
all cVDPV2s and the 21 pre-VDPV2s included were isolated
from case patients in northern states, we compared
clinical features of WPV and NP-AFP cases from those states
only.
Comparisonsbetween casetypesfor categorical variableswere
made using v
2 tests for homogeneity or exact tests as necessary
or using Cochran-Mantel-Haenszel test to control for age.
Kruskal-Wallis tests were used for continuous variables. Pop-
ulation density mapping used LandScan (Oak Ridge National
Laboratory) estimates for 2007 compiled on a 30$330$ lati-
tude/longitude grid [36].
Virus Isolation and Characterization
Viruses in stool specimens were isolated in RD and L20B cells
in accordance with standard protocols [37] and were
characterized by reverse-transcriptase polymerase chain reaction
(RT-PCR) assays using enterovirus-speciﬁc and poliovirus
group-, serotype-, and Sabin strain-speciﬁc primer sets [38, 39]
and enzyme-linked immunosorbent assays using cross-absorbed
hyperimmune sera [37, 40]. Since August 2006, vaccine-related
poliovirus isolates were screened for VDPVs using areal-time RT-
PCR assay [20]. VDPVs were identiﬁed by VP1 sequencing [41].
Outbreak Trends
Changes in annualized incidence of cVDPV2 and pre-VDPV2
cases for birth cohorts (2000 to mid-2010) were assessed for the
period January 2005–June 2010. The denominator for incidence
calculations was the sum of annual state-level population esti-
mates based on the 2006 national census adjusted for infant and
child survival and population growth [22, 23, 30].
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OPV coverage data are available from administrative reporting
of routine immunization, coverage surveys [29-33], and im-
munization histories collected duringinvestigation ofAFP cases.
Because national administrative coverage estimates have been
consistently higher than survey estimates [29], we used data
from surveys and AFP surveillance.
Many immunization coverage surveys of children aged 12–23
months were conducted during 2003–2008 [30-33]. Vaccination
recall histories (total doses, not distinguishing between RI or
SIAs) collected during investigation of case patients with NP-
AFP aged 6–35 months in 2005 were used as a coverage proxy
for the SIA target population. Vaccination history was an ex-
clusive indicator of PV2-speciﬁc immunization prior to the
introduction of mOPV SIAs in March 2006, because SIAs after
that date included different vaccine formulations. Demographic
and Health Survey coverage history of >3 DTP doses (a proxy
for >3 RI OPV doses) for children aged 12–23 months in 2008
(2007 birth cohort) [30] was mapped by state to reﬂect the
immunitystatus against PV2forthepopulation atriskforWPV,
cVDPV2, and pre-VDPV2 early in the outbreak.
Risk Assessment
State-level cumulative incidence rates of cVDPV2/pre-VDPV2
cases were compared with coverage levels and estimates of the
proportion of children without polio immunization (OPV0).
Correlations of incidence with coverage were assessed using 3
proxies for state-level routine OPV3 coverage: OPV3 history
amongcasepatients withNP-AFPaged6–35monthsfrom2005,
DTP3 coverage from the 2006 NICS (2005 birth cohort), and
DTP3 coverage from the 2008 Demographic and Health Survey
(2007 birth cohort). The proportion of OPV0 children was also
taken from each coverage data source; for surveys, this was es-
timated as 100% – %DTP1. LOESS, a method using local
polynomial regression ﬁtting [42], was used to describe the
correlation between estimated OPV3 coverage (or OPV0) and
incidence of cVDPV2/pre-VDPV2 cases. Spearman rank
correlation coefﬁcients were used to quantify the strength of
correlation.
RESULTS
Descriptive Epidemiology
From July 2005 through June 2010, 315 cVDPV2 cases, 21 pre-
VDPV2 cases, and 10 cVDPV2/pre-VDPV2 coinfections de-
tected in WPV cases were identiﬁed in Nigeria (Figure 2). One
cVDPV2 case was detected in July 2005, 21 cases were detected
in 2006 (after March 2006), 68 cases were detected in 2007, 63
cases were detected in 2008, 153 cases were detected in 2009, and
9 cases were detected through June 2010. Sixteen pre-VDPV2
cases were detected in 2006, 4 were detected in 2007, and 1 was
detected in 2009.
Median ages for case patients with cVDPV2, pre-VDPV2, and
WPV (including co-infections) were similar (24 months), and
case patients were predominantly male (57%–64%) (Table 1).
The clinical presentations (ie, fever at onset, asymmetric paral-
ysis, rapid progression of paralysis, and number of affected
limbs) were also similar for these 3 categories of cases. Among
children with 60-day evaluation reported, the proportion with
residual paralysis was not signiﬁcantly different for those with
cVDPV2 cases (77%), compared with those who had WPV
(85%) or pre-VDPV2 cases (100%) (Table 1).
Most case patients with cVDPV2, pre-VDPV2, and WPV
were undervaccinated children (Tables 1 and 2). Only 43% of
patients with cVDPV2, 15% of those with pre-VDPV2, and 28%
of those with WPV received >3 doses of OPV; 20% of patients
with cVDPV2, 50% of those with pre-VDPV2, and 36% of those
with WPV received no OPV dose. By contrast, OPV3 coverage
was signiﬁcantly higher (64%; P , .001) for patients with NP-
AFP than all other case types, and the proportion OPV0 was
signiﬁcantly lower (13%; P , .001) when controlled for age.
During the 5 years of emergence and spread, cases were re-
ported from all 7 northwest (NW) zone states, 4 of 6 northeast
(NE) zone states, and 5 of 7 north central (NC) zone states
(Figures 1 and 3). The NW zone accounted for 249 cVDPV2
cases (79%) and 17 pre-VDPV2 cases (81%), and 7 of 10 WPV-
mixed infections; the NE zone accounted for 42 cVDPV2 cases
(13%) and 3 pre-VDPV2 cases (14%), and 3 of 10 WPV-mixed
infections; and the NC zone accounted for 24 cVDPV2 cases
(8%)and1pre-VDPV2case(5%).Amajorfocusoftheoutbreak
was Kano State, which has high population density (Figure 1)
and accounted for 95 (36%) of 266 NW zone cVDPV2/pre-
VDPV2 cases during the entire outbreak period and 23 (62%) of
37 cVDPV2/pre-VDPV2 cases in 2006 (Figure 3). The geo-
graphic distribution of WPV for the period July 2005-June
2010 showed a similar pattern, with 3312 (98%) of 3390 cases
in the northern states, including 2508 (74%) in the NW zone,
604 (18%) in the NE zone, and 200 (6%) in the NC zone.
The ﬁrst cVDPV2 outbreak case occurred in Bauchi state in
the NE zone in July 2005. On basis of the 1.1% VP1 nt di-
vergence of the isolate, we estimate that the initiating OPV dose
was administered in mid-2004. At least 7 independent cVDPV2
lineages, identiﬁed by VP1 sequence relationships, emerged
during the period 2005–2009 (Figures 2 and 3). cVDPV2 line-
ages 1, 3, 4, and 7 were limited to 2–3 cases primarily localized
within a single state, but lineages 5 and 6 were associated
with 6–7 cases and spread to multiple states (Figure 3). Lineage
2, associated with 291 cVDPV2 cases, predominated in the NW
zone by late 2006 and spread widely across the northern states
into mid-2010. Of 21 pre-VDPV2 isolates, 16 (76%) were an-
cestral to subsequent cVDPV2 isolates (Figure 3); the remaining
5, including the pre-VDPV2 from mid-2009, were unrelated to
each other or to the cVDPV2 isolates and signaled additional
independent emergences.
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tOPV SIAs were implemented in the affected states 6 times an-
nually during 2004–2005 and in February 2006. Of 30 SIAs con-
ducted in the northern states during March 2006-June 2010, 16
usedmOPV1only,4usedmOPV3only,and3usedbivalentOPV
types1and3(bOPV)[1,13,43] (Figure2).FourtOPVSIAswere
conducted during March 2006–September 2007; no further
tOPV SIAs were conducted until May 2009 [13]. The monthly
incidence of cVDPV2/pre-VDPV2 cases, which averaged 5–6 per
month in 2007–2008, increased substantially during January–
June 2009, peaking at .30 cases per month during the period
April–May. Of 154 cases occurring in 2009, 71 (46%) were in
children born during 2007, who had the highest annualized in-
cidence of all birth cohorts, followed by children born in 2006
and 2008 (Figure 4). After 2 tOPV SIAs conducted in May and
August 2009, the monthly incidence decreased sharply to 0–3
cases during September 2009–June 2010 (total of 14) (Figure 2).
Risk Assessment
An inverse relationship was found between disease incidence
and type 2-containing OPV3 coverage (or DTP3 coverage
proxies) by state using coverage data from 2005 NP-AFP cases
(Figure 5A), NICS 2006 (Figure 5C), and Demographic and
Health Survey 2008 (Figure 5E). The risk of pre-VDPV2/
cVDPV2 emergence and spread nears 0 when OPV3 coverage
(or DTP3coverage proxies) exceeded 90% (2005NP-AFP),60%
(NICS 2006), or 55% (Demographic and Health Survey 2008).
Similarly, a positive relationship was found between pre-
VDPV2/cVDPV2 incidence and OPV0 coverage (Figure 5B, 5D,
and 5F). The LOESS curves indicate that the risks of pre-
VDPV2/cVDPV2 emergence and spread increases above 0 when
theproportionofOPV0childrenexceeded10%(2005NP-AFP),
25% (NICS 2006), or 20% (Demographic and Health Survey
2008). Some states with particularly high incidence and low
coverage clearly stand out; the northern-state annualized in-
cidence ofcVDPV2/pre-VDPV2cases was 0.09 cases per100,000
persons (n 5 336), yet state-level incidence was as high as 0.23
casesper100,000personsinZamfara(n539)and0.19casesper
100,000 persons in Kano (n 5 95).
DISCUSSION
The 336 pre-VDPV2/cVDPV2 cases and the 10 pre-VDPV2/
cVDPV2-WPV coinfections found in northern Nigeria during
the period July 2005–June 2010 constitute the largest reported
outbreak of cVDPV infection in terms of the number of cases
and in geographic extent [5, 17, 20, 21]. Phylogenetic analyses
identiﬁed >7 independent cVDPV outbreak lineages with
a combined 5 years of transmission despite intermittent tOPV
SIAs [5, 13].
Figure 2. Acute flaccid paralysis (AFP) cases associated with circulating vaccine-derived poliovirus type 2 (cVDPV2), pre-VDPV2, and co-infections with
wild poliovirus type 1 (WPV1) or type 3 (WPV3), by month of onset and timing of supplementary immunization activities (SIAs) for northern states by oral
poliovirus vaccine (OPV) formulation, Nigeria, 1 January 2005 through 30 June 2010. bOPV, bivalent oral poliovirus vaccine types 1 and 3; mOPV1,
monovalent oral poliovirus vaccine type 1; mOPV3, monovalent oral poliovirus vaccine type 3; tOPV, trivalent oral poliovirus vaccine.
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Wild Poliovirus (WPV), and Nonpolio Acute Flaccid Paralysis (NP-AFP), Northern Nigeria, January 2005–June 2010
Variable
a cVDPV2 pre-VDPV2 WPV
b NP-AFP P
c
No. of cases by year of onset
2005 1 0 804 2532
2006 21 16 1108 2546
2007 68 4 273 2320
2008 63 0 771 2878
2009 153 1 351 3041
2010
d 9 0 5 1683
Total 315 21 3312 15,000
Demographic characteristics
Male sex 64 62 57 57 .09
Age, months
Mean 27 24 26 36
Median (range) 24 (0–270) 24 (5–60) 24 (0–172) 26 (0–784) ,.001
e,f
Interquartile range 18–36 12–30 17–34 18–45
Region
f and population, per 2006 census ,.001
North West (n 5 35,786,944) 79 81 76 48
North Central (n 5 20,266,257) 8 5 6 29
North East (n 5 18,971,965) 13 14 18 23
OPV coverage, doses
g,h ,.001
02 0 5 0 3 6 1 3
1-2 d 37 35 36 23
. 34 3 1 5 2 8 6 4
Clinical features
Fever at onset
i 99 100 99 98 ,.001
Asymmetric paralysis
j 77 76 75 77 .07
Rapid progression of paralysis (<3 days)
i 99 100 99 98 .03
k
No. of affected limbs
l .006
00 0 1 0
15 6 6 2 5 2 5 4
24 0 3 3 4 2 4 2
34 0 3 2
40 5 2 2
60-day follow-up status
Percentage of subjects with follow-up data
m 49 29 21 10
Status
n ,.001
k
Residual paralysis 77 100 85 56
No residual paralysis 20 0 13 41
Lost to follow-up 2 0 1 1
Died before follow-up 1 0 1 2
NOTE. Data are percentage of subjects, unless otherwise indicated. OPV, oral poliovirus vaccine.
a Data on variables analyzed are missing for some cases; ,2% of data are missing for any one variable, except that OPV data are missing for 3% of cVDPV2 cases, 4% of pre-
VDPV2 cases, 3% of WPV and WPV/cVDPV2 coinfection cases, and 3% of NP-AFP cases.
b WPV cases include 8 cases with WPV and cVDPV2 coinfection and 2 cases with WPV and pre-VDPV2 coinfection.
c Determined using the v
2 test, unless otherwise indicated.
d Data available from 1 January through 31 July 2010.
e The Kruskal-Wallis test for comparison of medians was used.
f Although the overall comparison is statistically signiﬁcant, the only signiﬁcant pairwise comparisons are between cVDPV2, pre-VDPV2, and WPV with NP-AFP cases.
g Reﬂects total OPV doses, including tOPV, mOPV1, mOPV3, and bOPV (in 2010).
h Overall comparison is statistically signiﬁcant. All pairwise comparisons between case types are signiﬁcant, with the exception of the comparison between WPV and pre-
VDPV2 cases.
i Overall comparisonis statistically signiﬁcant. Pairwise comparisonsbetween case types are not signiﬁcant, with theexception of the comparison betweenWPV andNP-AFP
cases.
j Overall comparison is not statistically signiﬁcant. The only signiﬁcant pairwise comparison is between WPV and NP-AFP cases.
k Determined using the Monte Carlo estimate of exact v
2test, with 10,000 samples.
l Overallcomparisonis statisticallysigniﬁcant.Pairwisecomparisonsbetweencasetypesare notsigniﬁcant,with theexceptionof the comparisonbetweencVDPV2andWPV
to NP-AFP cases.
m Follow-up data were not available for 2010 cases.
n The overall comparison is statistically signiﬁcant. Signiﬁcant pairwise comparisons are seen between cVDPV2 to WPV and, cVDPV2 and WPV to NP-AFP cases.
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that the key risk factor for cVDPV emergence and spread is low
population immunity [4, 10, 44]. Jenkins et al [21] reached
similar conclusions using NP-AFP and NICS 2006 data to es-
timate coverage with type 2-containing OPV. When we at-
tempted to estimate the tOPV coverage threshold necessary to
prevent cVDPV2 emergence and spread in northern Nigeria,
there were broad inconsistencies in coverage estimates for
states by source. The OPV history of persons with NP-AFP by
caregiver recall, expected to be higher than DTP3 estimates
due to SIA doses, is of uncertain accuracy and representa-
tiveness. Although the LOESS curve shapes differed, NICS
2006 and Demographic and Health Survey 2008 data described
similar thresholds of tOPV coverage (60% vs 55%, re-
spectively) and of zero-dose (25% vs 20%, respectively). All
available data suggest that the tOPV SIAs, despite substantial
coverage gaps, were the primary sources of PV2 immunity for
the at-risk population in the northern states. Because the only
other source of vaccine-induced PV2 immunity was from low-
coverage RI with tOPV, PV2 immunity gaps widened with the
emphasis on the use of mOPV1 and mOPV3 in SIAs. The
independent emergence of >7 cVDPV2 lineages during 2005–
2009 suggests that population immunity to PV2 fell further
below a critical threshold in many areas across the northern
states. The burst of cases in January–June 2009 signaled the
widening PV2 immunity gap 4 years into the outbreak,
particularly among children reaching 2 years of age who had
not received tOPV in SIAs during the period October 2007–
April 2009. Because of the high immunogenicity of the Sabin 2
vaccine strain [2, 45, 46], 1 or 2 tOPV SIAs reaching most
unvaccinated children should quickly close immunity gaps to
PV2 [5, 10]. The sharp decrease in monthly incidence after
June 2009 suggests coverage was higher during the tOPV SIAs
in May and August 2009 than in previous tOPV SIAs, con-
sistent with trends in WPV incidence, but not yet sufﬁcient to
interrupt cVDPV transmission to date [13].
MostpreviouscVDPVoutbreakswererecognizedatleast1year
afterinitialemergence[9, 18, 44, 47], because low OPV coverage
is usually accompanied by suboptimal AFP surveillance perfor-
mance. By contrast, AFP surveillance in Nigeria was generally
gooddespiteweaknessesinOPVcoverage,allowinginvestigation
of early outbreak events, especially the role of pre-VDPVs.
Available clinical follow-up data from this report showed that
.75% of case patients with cVDPV2 and with WPV AFP had
residual paralysis after 60 days, similar to the report of Jenkins
et al [21]. This ﬁnding is consistent with previous reports of
outbreaks of cVDPV1 infection, for which a cumulative 74% of
cVDPV-associated AFP cases involved residual paralysis typical
of poliomyelitis [9, 18, 44, 47]; outcome data were not reported
from previous outbreaks of cVDPV2 infection [5, 10]. We also
found that all case patients with pre-VDPV2 with follow-up data
had residual paralysis after 60 days. Thus, both pre-VDPV2s and
Table 2. Distribution of Caretaker Recall History of Oral Poliovirus Vaccine (OPV) Vaccination Status for Children with Acute Flaccid
Paralysis (AFP), by Case Classification, Northern Nigeria, January 2005–June 2010
No. (%) of subjects
Year of onset No. of OPV doses cVDPV2/pre-VDPV2 WPV NP-AFP
2005 0 1 (100) 378 (48) 606 (25)
1-2 0 244 (31) 631 (26)
>3 0 167 (21) 1221 (50)
2006 0 15 (45) 408 (38) 442 (18)
1-2 11 (33) 417 (39) 684 (28)
>3 7 (21) 236 (22) 1302 (54)
2007 0 28 (39) 72 (27) 260 (11)
1-2 28 (39) 101 (38) 644 (28)
>3 15 (21) 96 (36) 1383 (60)
2008 0 10 (16) 231 (31) 302 (11)
1-2 26 (42) 293 (39) 674 (24)
>3 26 (42) 231 (31) 1850 (65)
2009 0 16 (11) 56 (16) 177 (6)
1-2 53 (35) 112 (32) 554 (18)
>3 82 (54) 180 (52) 2280 (76)
2010 0 1 (11) 1 (20) 72 (4)
1-2 4 (44) 4 (80) 206 (12)
>3 4 (44) 0 1385 (83)
NOTE. Percentages may not sum to 100 due to rounding. OPV doses can include trivalent, monovalent type 1, monovalent type 3, and bivalent types 1 and 3
formulations. cVDPV2, circulating vaccine-derived poliovirus type 2; NP-AFP, nonpolio AFP; WPV, wild poliovirus.
904 d JID 2011:203 (1 April) d Wassilak et al.Figure 3. Map of Nigeria showing state by proportion of children with diphtheria-tetanus-pertussis dose 3 (DPT3) coverage at 12–23 months of age (a
proxy for oral poliovirus vaccine dose 3 or more [OPV31] coverage) estimated from the 2008 Demographic Health Survey (2007 birth cohort) overlaid with
cases of circulating vaccine-derived poliovirus type 2 (cVDPV2), pre-VDPV2, or coinfections with wild poliovirus type 1 (WPV1) or type 3 (WPV3), 2005–
2010 (A–F). 1 dot equals 1 case. Cases were mapped randomly within local government area borders. FCT, Federal Capital Territory.
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to cause paralytic poliomyelitis. These data have some limi-
tations in that ,50% of persons with poliovirus-associated cases
underwent follow-up examination, and residual paralysis also
was reported in a high proportion of the 10% of persons with
NP-AFP who had follow-up data.
The ﬁnding that 16 of 21 pre-VDPV2s were ancestral to
subsequently observed cVDPV2 lineages strongly implicates
pre-VDPV2s as outbreak intermediates. Recognition of the
critical early role of pre-VDPVs in the outbreak has important
implications for global VDPV surveillance. The 1%demarcation
in VP1 nt divergence deﬁning VDPVs was established to
balance speciﬁcity with sensitivity in routine global VDPV sur-
veillance, while accommodating variations in rates and sites of
initial nt substitution into the 3 Sabin strain genomes [4, 7, 48].
However, this outbreak demonstrates that the detection of
vaccine-related isolates with ,1% VP1 divergence may have
epidemiologic importance, especially in areas with known
population immunity gaps, particularly for PV2. Routine
screening for VDPVs in AFP surveillance by a combination
of molecular and antigenic analyses [5, 20, 37] may be
suitable for detecting early cVDPV1 and cVDPV3 outbreak
isolates, but it may lack sensitivity for detecting cVDPV2s
early in outbreaks. New real-time RT-PCR screening
procedures consistently ﬂag the Nigerian cVDPV2 and pre-
VDPV2 isolates for further analysis [20] (D. Kilpatrick;
personal communication). Timely detection of cVDPV
emergence will require ongoing, sensitive AFP surveillance
combined with epidemiologic and virologic screening and
analyses.
The cVDPV outbreak in Nigeria exempliﬁes the risks ac-
companying low RI OPV coverage and underscores the need to
balance poliovirus immunity to all serotypes in all populations.
In countries and areas where tOPV3 coverage in RI programs
remains low, achieving high coverage in SIAs using an appro-
priate mix of mOPVs, bOPV, and tOPV is essential to limit and
ultimately stop all poliovirus circulation.
Funding
Funding to pay the Open Access publication charges for this article was
provided by CDC funding.
Figure 4. Annual combined circulating vaccine-derived poliovirus type 2 (cVDPV2) and pre-VDPV2 case incidence rates, by year of birth and year
of onset, Nigeria, 1 July 2005 through 30 June 2010. Table insert, Cumulative number of supplementary immunization activities (SIAs) with
trivalent oral poliovirus vaccine (tOPV) in the affected states with cVDPV2 and pre-VDPV2 cases by year of birth since 2000 and year of onset, Nigeria,
2005–2010.
906 d JID 2011:203 (1 April) d Wassilak et al.Figure 5. Cumulative incidence of combined circulating vaccine-derived poliovirus type 2 (cVDPV2) and pre-VDPV2, by state, compared with state oral
poliovirus vaccine (OPV) immunization coverage using LOESS polynomial regression line (r, Spearman rank correlation coefficients), Nigeria, 1 July 2005
through 30 June 2010. Estimated OPV31 (>3 doses of OPV) coverage (A) or absence of OPV vaccination (OPV0) (B) from caregiver recall histories for
children aged 6–59 months with nonpolio acute flaccid paralysis (NP-AFP) in 2005. Also shown are the estimated diphtheria-tetanus-pertussis dose 3
(DTP3) coverage at 12–23 months of age (C) or absence of vaccination (ie, 100% – %DTP dose 1 [DTP1], [1–DTP1]) (D) from the 2006 national
immunization coverage survey (NICS, 2005 birth cohort), as well as the estimated DPT3 coverage (E) or absence of vaccination (1–DTP1) (F) from the 2008
Demographic and Health survey (DHS, 2007 birth cohort). All correlations differed significantly from 0 (P ,.001).
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